DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
CNY 17.29
(0.93%)
CNY 17.29
(0.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.63 Billion CNY | 25.18% |
| 2022 | 1.42 Billion CNY | 36.54% |
| 2021 | 1.04 Billion CNY | -28.14% |
| 2020 | 1.44 Billion CNY | 57.69% |
| 2019 | 918.25 Million CNY | 27.84% |
| 2018 | 718.29 Million CNY | 13.42% |
| 2017 | 633.31 Million CNY | 9.47% |
| 2016 | 578.55 Million CNY | 5.6% |
| 2015 | 547.87 Million CNY | 33.18% |
| 2014 | 411.36 Million CNY | 30.34% |
| 2013 | 315.61 Million CNY | 30.81% |
| 2012 | 241.26 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 358.65 Million CNY | -40.66% |
| 2024 Q1 | 604.4 Million CNY | 4046.64% |
| 2024 Q3 | 298.41 Million CNY | -16.79% |
| 2023 Q4 | 14.57 Million CNY | -96.08% |
| 2023 Q1 | 684.08 Million CNY | 246.27% |
| 2023 Q2 | 548.69 Million CNY | -19.79% |
| 2023 FY | 1.77 Billion CNY | 25.18% |
| 2023 Q3 | 371.62 Million CNY | -32.27% |
| 2022 Q2 | 438.94 Million CNY | -10.85% |
| 2022 FY | 1.42 Billion CNY | 36.54% |
| 2022 Q4 | 197.55 Million CNY | -32.32% |
| 2022 Q3 | 291.89 Million CNY | -33.5% |
| 2022 Q1 | 492.39 Million CNY | 1288.3% |
| 2021 Q1 | 456.74 Million CNY | 74.61% |
| 2021 Q3 | 224.38 Million CNY | -44.02% |
| 2021 FY | 1.04 Billion CNY | -28.14% |
| 2021 Q2 | 400.84 Million CNY | -12.24% |
| 2021 Q4 | -41.43 Million CNY | -118.47% |
| 2020 Q3 | 368.49 Million CNY | -14.16% |
| 2020 Q2 | 429.25 Million CNY | 10.46% |
| 2020 FY | 1.44 Billion CNY | 57.69% |
| 2020 Q1 | 388.62 Million CNY | 120.26% |
| 2020 Q4 | 261.58 Million CNY | -29.01% |
| 2019 FY | 918.25 Million CNY | 27.84% |
| 2019 Q3 | 232.71 Million CNY | -11.74% |
| 2019 Q4 | 176.43 Million CNY | -24.18% |
| 2019 Q1 | 245.42 Million CNY | 45.91% |
| 2019 Q2 | 263.68 Million CNY | 7.44% |
| 2018 Q1 | 195.85 Million CNY | 35.05% |
| 2018 Q4 | 168.2 Million CNY | -0.3% |
| 2018 FY | 718.29 Million CNY | 13.42% |
| 2018 Q2 | 185.53 Million CNY | -5.27% |
| 2018 Q3 | 168.7 Million CNY | -9.07% |
| 2017 Q3 | 156.49 Million CNY | -9.24% |
| 2017 Q1 | 159.36 Million CNY | 20.18% |
| 2017 Q2 | 172.43 Million CNY | 8.2% |
| 2017 FY | 633.31 Million CNY | 9.47% |
| 2017 Q4 | 145.02 Million CNY | -7.33% |
| 2016 Q2 | 144.4 Million CNY | -4.9% |
| 2016 Q1 | 151.84 Million CNY | 0.0% |
| 2016 Q3 | 149.69 Million CNY | 3.66% |
| 2016 Q4 | 132.6 Million CNY | -11.42% |
| 2016 FY | 578.55 Million CNY | 5.6% |
| 2015 Q1 | 148.06 Million CNY | 0.0% |
| 2015 Q2 | 148.06 Million CNY | 0.0% |
| 2015 FY | 547.87 Million CNY | 33.18% |
| 2014 FY | 411.36 Million CNY | 30.34% |
| 2013 FY | 315.61 Million CNY | 30.81% |
| 2012 FY | 241.26 Million CNY | 0.0% |